2025
N-methyl-d-aspartate receptor hypofunction causes recurrent and transient failures of perceptual inference
Weilnhammer V, Rothkirch M, Yilmaz D, Fritsch M, Ptasczynski L, Reichenbach K, Roediger L, Corlett P, Sterzer P. N-methyl-d-aspartate receptor hypofunction causes recurrent and transient failures of perceptual inference. Brain 2025, 148: 1531-1539. PMID: 39821016, PMCID: PMC12073972, DOI: 10.1093/brain/awaf011.Peer-Reviewed Original ResearchN-methyl-D-aspartate receptorsN-methyl-D-aspartateN-methyl-D-aspartate receptor hypofunctionS-ketamineSymptoms of schizophreniaDissociation of perceptionsHealthy human participantsExternal sensory signalsReceptor hypofunctionSensory signalsNMDAR hypofunctionPerceptual inferenceCase-control studyInternal predictionsHuman participantsPlacebo-ControlledDouble-blindCross-over experimentHypofunctionSchizophreniaParanoidPerceptionSCZ
2024
Relationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia
Wang X, Chen W, Gou M, Li W, Li N, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Pan S, Luo X, Zhang P, Huang J, Tian L, Li C, Tan Y. Relationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia. BMC Psychiatry 2024, 24: 480. PMID: 38956509, PMCID: PMC11218378, DOI: 10.1186/s12888-024-05796-y.Peer-Reviewed Original ResearchConceptsPositive and Negative Syndrome ScalePlasma TNF-a levelsAgitation symptomsPANSS-ECEpisode patientsTNF-a levelsPositive and Negative Syndrome Scale total scorePANSS-EC scoreNegative Syndrome ScaleSymptoms of schizophreniaPathophysiology of schizophreniaEnzyme-linked immunosorbent assayTNF-aR1 levelSyndrome ScalePlasma levels of tumor necrosis factor-alphaLevels of tumor necrosis factor-alphaSchizophreniaTotal scoreTumor necrosis factor-alphaNecrosis factor-alphaPlasma TNF-aHealthy controlsFEPImmune abnormalitiesIntranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial
Saporta-Wiesel L, Feldman R, Levi L, Davidson M, Burshtein S, Gur R, Zagoory-Sharon O, Amiaz R, Park J, Davis J, Weiser M. Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial. Schizophrenia Bulletin Open 2024, 5: sgae022. PMID: 39502135, PMCID: PMC11535855, DOI: 10.1093/schizbullopen/sgae022.Peer-Reviewed Original ResearchSocial skills trainingSymptoms of schizophreniaSkills trainingSupportive psychotherapyNegative symptoms of schizophreniaTreatment of negative symptomsSocial interactionBaseline to end-of-studyBlunted affectNegative symptomsPANSS scoresIntranasal oxytocinPositive affectSocial dysfunctionSchizophreniaRandomized Controlled TrialsTotal scoreSocial behaviorPost Hoc AnalysisPANSSPsychotherapyOxytocinHigh dose oxytocinAffectEnd-of-studyPsychopharmacological Treatment of Schizophrenia
Singh N, Ganesh S, D'Souza D. Psychopharmacological Treatment of Schizophrenia. 2024, 729-737. DOI: 10.1016/b978-0-323-95702-1.00177-9.Peer-Reviewed Original ResearchAntipsychotic drugsPositive symptoms of schizophreniaPharmacological treatment of schizophreniaTreatment-resistant schizophreniaPharmacological treatmentSymptoms of schizophreniaTreatment of schizophreniaAcute psychotic episodeNeuroleptic malignant syndromeNegative symptomsPositive symptomsExtrapyramidal symptomsPsychotic episodeCognitive deficitsCognitive symptomsMalignant syndromeSchizophreniaPrevent relapseSide effectsMaintenance treatmentLong-actingDopamineAssociated with significant side effectsMedication adherenceProportion of patients
2020
An 18-month longitudinal study of suicidality in patients diagnosed with schizophrenia
Buchanan A, Sint K, Stefanovics E, Rosenheck R. An 18-month longitudinal study of suicidality in patients diagnosed with schizophrenia. Schizophrenia Research 2020, 224: 102-107. PMID: 33046335, DOI: 10.1016/j.schres.2020.09.019.Peer-Reviewed Original ResearchConceptsRisk factorsSevere suicidalityHazard ratioDepression scoresIntervention Effectiveness (CATIE) trialMultivariate hazard ratiosHigh-risk groupImportant risk factorPotential risk factorsProportional hazards modelPutative risk factorsSubjects' depression scoresSymptoms of schizophreniaUnstable illnessAntipsychotic treatmentPatient populationSelf-reported suicide attemptsClinical changesEffectiveness trialHigh riskPsychotic decompensationPsychotic symptomsHazards modelMultivariate analysisPrior suicidalityThe Effects of Augmenting Clozapine with Oxytocin in Schizophrenia: An Initial Case Series
Marotta RF, Buono FD, Garakani A, Collins E, Cerrito B, Rowe DR. The Effects of Augmenting Clozapine with Oxytocin in Schizophrenia: An Initial Case Series. Annals Of Clinical Psychiatry 2020, 32: 90-96. PMID: 32343282, DOI: 10.1177/104012372003200211.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment-resistant schizophreniaNegative symptomsAtypical antipsychoticsRetrospective chart reviewInitial case seriesAugmentation of clozapineChronic psychotic illnessNegative Syndrome ScaleYoung adult inpatientsSymptoms of schizophreniaParent/guardian reportsChart reviewCase seriesAdult inpatientsProspective studyAntipsychotic medicationClinical reviewTherapeutic responsePsychotic illnessTreatment approachesSyndrome ScalePositive symptomsTreating psychiatristSymptomsSustained treatment
2018
Correlates of frequent gambling and gambling-related chasing behaviors in individuals with schizophrenia-spectrum disorders
Yakovenko I, Fortgang R, Prentice J, Hoff RA, Potenza MN. Correlates of frequent gambling and gambling-related chasing behaviors in individuals with schizophrenia-spectrum disorders. Journal Of Behavioral Addictions 2018, 7: 375-383. PMID: 29788756, PMCID: PMC6174591, DOI: 10.1556/2006.7.2018.31.Peer-Reviewed Original ResearchMeSH KeywordsAge of OnsetAmbulatory CareCross-Sectional StudiesFemaleGamblingGenetic Predisposition to DiseaseHumansMaleMiddle AgedMotivationPsychiatric Status Rating ScalesPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySelf ReportSeverity of Illness IndexSubstance-Related DisordersConceptsSchizophrenia/schizoaffective disorderSchizoaffective disorderCo-occurring disordersDSM-IV criteriaSymptoms of schizophreniaSchizophrenia spectrum disordersPsychotic spectrum disordersHigh prevalenceFamily historyGreater gambling involvementSchizophreniaDisordersLower functioningContinuum of severityHallmark featureMethods DataSample of individualsGambling disorderIndividualsCorrelates
2016
The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models
Khlestova E, Johnson JW, Krystal JH, Lisman J. The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models. Journal Of Neuroscience 2016, 36: 11151-11157. PMID: 27807157, PMCID: PMC5148234, DOI: 10.1523/jneurosci.1203-16.2016.Peer-Reviewed Original ResearchConceptsNMDAR antagonistsNMDA receptor hypofunction hypothesisDifferent NMDAR subtypesHealthy human subjectsSymptoms of schizophreniaPsychotogenic effectsNMDA receptorsNMDAR subtypesSchizophrenia modelKetamine's abilityNegative symptomsKetamineMultiple subtypesPsychotic statesPreferential involvementSchizophreniaAntagonistGluN2CSubtypesReceptorsEEG powerHuman subjectsNMDARSymptomsΔ oscillationsAssociation of catechol-O-methyltransferase Val108/158 Met genetic polymorphism with schizophrenia, P50 sensory gating, and negative symptoms in a Chinese population
Mao Q, Tan Y, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Zhang X. Association of catechol-O-methyltransferase Val108/158 Met genetic polymorphism with schizophrenia, P50 sensory gating, and negative symptoms in a Chinese population. Psychiatry Research 2016, 242: 271-276. PMID: 27315458, DOI: 10.1016/j.psychres.2016.04.029.Peer-Reviewed Original ResearchConceptsPCR-restriction fragment length polymorphismSchizophrenic patientsP50 deficitsNegative symptomsChinese populationNegative Syndrome ScaleRisk of schizophreniaSymptoms of schizophreniaP50 sensory gatingVal allele carriersHan Chinese populationRole of COMTCerebral cortexClinical symptomatologyHealthy controlsNegative subscoreAllele carriersMetS individualsMet/Met individualsControl groupSensory gatingSyndrome ScaleGenotype distributionP50 gatingSchizophrenic subjects
2014
Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia
Xu K, Krystal JH, Ning Y, Chen da C, He H, Wang D, Ke X, Zhang X, Ding Y, Liu Y, Gueorguieva R, Wang Z, Limoncelli D, Pietrzak RH, Petrakis IL, Zhang X, Fan N. Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. Journal Of Psychiatric Research 2014, 61: 64-72. PMID: 25560772, PMCID: PMC4445679, DOI: 10.1016/j.jpsychires.2014.12.012.Peer-Reviewed Original ResearchConceptsKetamine groupNegative Syndrome ScaleSchizophrenia groupSyndrome ScaleN-methyl-D-aspartate (NMDA) glutamate receptor antagonistGlutamate receptor antagonistsPotential confounding factorsEarly course schizophreniaSymptom dimensionsSymptoms of schizophreniaReceptor antagonistChronic schizophreniaHealthy subjectsKetamine abuseSchizophrenia psychosisSchizophrenia patientsConfounding factorsSymptom severitySymptomsInpatientsSchizophreniaPsychosisKetamine usersDissociation symptomsPrincipal component factor analysisGone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan R, Wilkinson ST, D’Souza D. Gone to Pot – A Review of the Association between Cannabis and Psychosis. Frontiers In Psychiatry 2014, 5: 54. PMID: 24904437, PMCID: PMC4033190, DOI: 10.3389/fpsyt.2014.00054.BooksPsychotic disordersFamily historyEmergence of psychosisPolymorphisms of COMTPublic health policySymptoms of schizophreniaTrigger relapsePsychosis outcomesHigh riskEpidemiological studiesAcute exposurePsychotomimetic symptomsPsychophysiological abnormalitiesPersistent effectsCognitive deficitsCannabis useHealth policyCannabinoidsSymptomsGenetic factorsCannabisChildhood traumaDisordersStandard criteriaWarrants serious considerationInsight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China
Mohamed S, Rosenheck R, He H, Yuping N. Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China. Social Psychiatry And Psychiatric Epidemiology 2014, 49: 1063-1070. PMID: 24549835, DOI: 10.1007/s00127-014-0824-1.Peer-Reviewed Original ResearchConceptsDrug Attitude InventorySchizophrenia symptomsPsychiatric hospitalOverall severityMeasures of insightGuangzhou Psychiatric HospitalTime of admissionBenefits of medicationsLarge psychiatric hospitalNegative Syndrome ScaleTreatment Attitudes QuestionnaireSymptoms of schizophreniaAcceptance of medicationHospitalized patientsAntipsychotic treatmentDAI scoresChronic schizophreniaMedicationsAnalysis of covarianceSyndrome ScaleMental illnessBivariate analysisSymptomsLarger studySchizophreniaSymptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia
Stefanovics EA, Krystal JH, Rosenheck RA. Symptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. Comprehensive Psychiatry 2014, 55: 887-895. PMID: 24602497, DOI: 10.1016/j.comppsych.2014.01.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntipsychotic AgentsChronic DiseaseCombat DisordersDiagnosis, DifferentialDouble-Blind MethodFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesPsychometricsRisperidoneSchizophreniaSchizophrenic PsychologyStress Disorders, Post-TraumaticVeteransYoung AdultConceptsPost-traumatic stress disorderNegative Syndrome ScaleSyndrome ScalePTSD samplePlacebo-controlled trialPsychosis-related factorsClinical trial patientsClinical Antipsychotic TrialsT-testSchizophrenia sampleExploratory factor analysisSymptoms of schizophreniaMilitary-related post-traumatic stress disorderSymptom structureAdjunctive risperidoneTrial patientsTraumatic Stress DisorderAntipsychotic TrialsSecondary data analysisSevere symptomsIndependent factorsDepressive factorsPatientsSymptom ratingsStress disorder
2013
Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-d-aspartate receptor hypofunction under urethane anesthesia
Kiss T, Feng J, Hoffmann W, Shaffer C, Hajós M. Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-d-aspartate receptor hypofunction under urethane anesthesia. Neuroscience 2013, 237: 255-267. PMID: 23396086, DOI: 10.1016/j.neuroscience.2013.01.058.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsBiphenyl CompoundsCarrier ProteinsCerebral CortexDelta RhythmDizocilpine MaleateElectric StimulationElectroencephalographyExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsHippocampusMiceMice, Inbred C57BLMice, KnockoutNerve Tissue ProteinsNeuronsRatsRats, Sprague-DawleyReceptors, N-Methyl-D-AspartateSulfonamidesTheta RhythmUrethaneConceptsN-methyl-D-aspartate receptorsMK-801WT miceN-methyl-D-aspartate (NMDA) receptor hypofunctionTheta oscillationsMK-801 challengeWild-type miceField potentialsHippocampal field potentialsHippocampal neuronal networksPreclinical disease modelsSymptoms of schizophreniaNeuronal network oscillationsHippocampal theta oscillationsRhythmic thetaVentro-medial prefrontal cortexHippocampal theta powerNMDAR hypofunctionReceptor hypofunctionNMDAR expressionUrethane anesthesiaGlutamate neurotransmissionHealthy subjectsDelta activityHypomorphic mice
2011
Advancing drug discovery for schizophrenia
Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Saw A, Caron MG, George SR, Allen JA, Solis M. Advancing drug discovery for schizophrenia. Annals Of The New York Academy Of Sciences 2011, 1236: 30-43. PMID: 22032400, PMCID: PMC3787879, DOI: 10.1111/j.1749-6632.2011.06216.x.Peer-Reviewed Original ResearchTreatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O’Brien E, Jane JS, Dwan R, Dean E, Edens E, Arnaout B, Keegan K, Drew S, Petrakis I. Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2011, 7: 64-73. PMID: 26954912, DOI: 10.1080/15504263.2011.569440.Peer-Reviewed Original ResearchEfficacy of acamprosateAlcohol dependenceSchizophrenia spectrum disordersMedication treatmentComorbid schizophreniaSignificant group x time interactionGroup x time interactionComorbid alcohol dependenceAlcohol use disorderSymptoms of schizophreniaX time interactionAcamprosate groupComorbid conditionsTreatment trialsAbstinent patientsClinical trialsSpectrum disorderAcamprosateGeneral populationUse disordersPatientsSchizoaffective disorderPositive symptomsSchizophrenic symptomsConsecutive days
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptoms
2006
Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence
Ralevski E, Balachandra K, Gueorguieva R, Limoncelli D, Petrakis I. Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2006, 2: 53-69. DOI: 10.1300/j374v02n04_05.Peer-Reviewed Original ResearchCognitive functioningAlcohol dependenceFrontal lobe functioningComorbid alcohol dependenceSymptoms of schizophreniaAlcohol useFunctioningCognitionTreatment studiesSchizophreniaEffects of naltrexoneAlcohol reductionMemoryDrinking patternsAlcohol consumptionAttentionSecond objectiveWeeks of treatmentDeficitsFirst objectiveWeek 24Naltrexone treatmentWeek 12NaltrexonePatients
2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movements
1993
m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia
Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS. m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia. JAMA Psychiatry 1993, 50: 624-635. PMID: 8102048, DOI: 10.1001/archpsyc.1993.01820200034004.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleHealthy subjectsPsychiatric Rating ScalePositive symptomsSchizophrenic patientsPatient groupDouble-blind randomized comparisonVeterans Affairs Medical CenterRating ScaleNeuroleptic-free schizophrenic patientsFirst patient groupSerotonin partial agonistPrincipal outcome variableVisual analog scaleBaseline prolactin levelsHigher baseline levelsSymptoms of schizophreniaAnalog scaleRandomized comparisonAnxiogenic responseSum of scoresProlactin levelsSerotonergic systemSerotonin functionHormone levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply